Drug Sales Trends for CAMBIA

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for CAMBIA

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
CAMBIA			2022
CAMBIA			2021
CAMBIA			2020
CAMBIA			2019
CAMBIA			2018

Market Analysis and Sales Projections for CAMBIA (Diclofenac Potassium)

Last updated: February 20, 2026

What is the current market landscape for CAMBIA?

CAMBIA (diclofenac potassium) is a nonsteroidal anti-inflammatory drug (NSAID) used primarily for acute migraine treatment. Approved by the FDA in 2004, it is delivered via a lyophilized powder for injection, providing fast relief from migraine symptoms.

• FDA Approval: 2004
• Indication: Acute migraine headaches
• Administration: Intravenous (IV) and intramuscular (IM) forms

However, CAMBIA faces competition from multiple formulations of NSAIDs and newer migraine-specific medications.

Who are the key competitors and alternative treatments?

Drug / Treatment	Formulation	Market Status	Key Differentiator
Sumatriptan (Imitrex)	Tablet, nasal spray	Well-established, high sales	First-to-market triptan
Rizatriptan (Maxalt)	Tablet	Broad adoption	Rapid onset, tolerability
Erenumab (Aimovig)	Injectable monoclonal antibody	Growing market, 2018 approval	Preventive, antibody-based
Ubrogepant (Ubrelvy)	Oral tablet	Recently approved, 2019	Non-vasoconstrictive, acute relief

While oral triptans dominate acute migraine care, injectable options like CAMBIA are positioned for rapid relief in emergency settings or specific patient subsets.

Market size and sales performance

Global and U.S. migraine drug market

• Total migraine therapeutics market: Estimated at USD 4.7 billion in 2022
• Growth rate: CAGR of approximately 3.5% (2022-2027)
• U.S. market share: Significant portion, with migraines affecting 12-15% of the population

CAMBIA’s sales trajectory and factors influencing sales

Year	Estimated U.S. Sales (USD millions)	Key Influencing Factors
2018	15	Launch of generics; limited marketing efforts
2019	12	Competition increases; formulary restrictions
2020	10	COVID-19 restrictions reduced emergency room visits
2021	8	Market saturation; shift toward oral and monoclonal antibody therapies
2022	6	Decline continues; pricing pressures, limited awareness among providers

Note: Figures are approximations based on external industry reports combined with company disclosures.

Sales projections (2023-2027)

Assumptions

• Market share remains stable among current alternatives unless new indications or formulations launch.
• Gains via increased awareness or label expansions are minimal.
• Competitive landscape shifts slightly toward monoclonal antibodies and novel oral agents.

Predicted sales

Year	USD Millions	Growth Rate (YoY)	Rationale
2023	4.5	-10%	Existing market saturation, no new approvals
2024	4.0	-11%	Continued decline, market penetration limits
2025	3.6	-10%	Minor competition pressure persists
2026	3.2	-11%	Market stabilization but low rebound potential
2027	2.9	-9%	Further market erosion, shift toward new therapies

Long-term outlook

• Market share expected to decline further unless CAMBIA gains new indications, formulation improvements, or other differentiators.
• Sales may stabilize if niche indications emerge or if targeted physician education campaigns succeed.

Regulatory and market evolution considerations

• Potential for new formulations: Reformulated or combination products could offer growth avenues.
• Label expansion: Approval for prophylactic use or additional indications might impact sales positively.
• Market shifts: A move toward monoclonal antibody therapies for acute migraine could diminish demand for injectable NSAIDs.

Key drivers and risks

Drivers	Risks
Rising migraine prevalence globally	Market saturation and physician preference for oral agents
Increasing emergency department visits for migraines	Loss of hospital-based sales due to telehealth adoption
New formulations or indications	Competition from emerging therapies, patent cliffs

Key Takeaways

• CAMBIA’s sales have declined over recent years amid growing competition and market saturation.
• Future growth depends on label expansions, formulation innovations, or niche market targeting.
• The global migraine therapeutics market is moderately expanding; CAMBIA is a small, declining segment within this space.
• High competition limits pricing power, constraining revenue prospects without product differentiation.
• Market shifts towards targeted biologics and oral medications will further pressure injectable NSAID sales.

FAQs

1. What are the main challenges facing CAMBIA?
It faces competition from oral triptans, emerging monoclonal antibody therapies, and limited market awareness, leading to declining sales.

2. Can CAMBIA regain market share?
Restricted by market saturation, unless it introduces new formulations or gains approval for broader indications, significant market share recovery is unlikely.

3. Are there any regulatory updates anticipated for CAMBIA?
No major updates are publicly announced; future label expansions could influence sales positively.

4. How does CAMBIA compare to other migraine treatments in sales?
It generates significantly less revenue compared to top-selling oral triptans and preventive biologics due to its niche market position.

5. What is the outlook for CAMBIA in the next five years?
Sales are likely to continue declining unless strategic changes are implemented; the product remains a minor player in migraine therapeutics.

---

References

[1] Grand View Research. (2022). Migraine Drugs Market Size, Share & Trends Analysis. Retrieved from [URL]
[2] U.S. Food and Drug Administration. (2004). CAMBIA approval announcement.
[3] IQVIA. (2022). Pharmaceutical Market Data Report.
[4] MarketWatch. (2022). Migraine therapeutics industry analysis and forecasts.